The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.
Martin Dyer
Honoraria - Ono Pharmaceutical
Research Funding - Ono Pharmaceutical
Claire Hutchinson
Research Funding - Ono Pharmaceutical
Simon Rule
No relevant relationships to disclose
Nimish Shah
No relevant relationships to disclose
Gilles A. Salles
Honoraria - Celgene; Gilead Sciences; Janssen
Lionel Karlin
Honoraria - Celgene; Janssen
Franck Morschhauser
Honoraria - Celgene; Mundipharma; Ono Pharmaceutical ; Roche
Louis Terriou
No relevant relationships to disclose
Christopher Fegan
Honoraria - Ono Pharmaceutical
Andrew Davison
No relevant relationships to disclose
Guillaume Cartron
Honoraria - Ono Pharmaceutical
Andrew Saunders
Consultant or Advisory Role - Ono Pharmaceutical ; Pharmacyclics
Hideyuki Honda
Employment or Leadership Position - Ono Pharmaceutical
John Sharpe
Employment or Leadership Position - Ono Pharmaceutical
Toshio Yoshizawa
Employment or Leadership Position - Ono Pharmaceutical
Tomoko Yasuhiro
Employment or Leadership Position - Ono Pharmaceutical
Kazuhito Kawabata
Employment or Leadership Position - Ono Pharmaceutical
Hiroshi Awata
Employment or Leadership Position - Ono Pharmaceutical
Joseph Birkett
Employment or Leadership Position - Ono Pharmaceutical